BAY-069 is a potent dual inhibitor of BCAT1/2 (branched-chain amino acid transaminases), with IC50 values of 31 nM for BCAT1 and 153 nM for BCAT2. It demonstrates high cellular activity, excellent selectivity, and is used as an in vitro probe.

BAY-069 is a potent dual inhibitor of BCAT1/2 (branched-chain amino acid transaminases), with IC50 values of 31 nM for BCAT1 and 153 nM for BCAT2. It demonstrates high cellular activity, excellent selectivity, and is used as an in vitro probe.

JNJ-64264681 is an orally active, irreversible covalent inhibitor of Bruton’s tyrosine kinase (BTK) with potent whole blood activity and exceptional kinome selectivity. It exhibits potential efficacy in treatment for B-cell malignancies and autoimmune disorders.

JNJ-64264681 is an orally active, irreversible covalent inhibitor of Bruton’s tyrosine kinase (BTK) with potent whole blood activity and exceptional kinome selectivity. It exhibits potential efficacy in treatment for B-cell malignancies and autoimmune disorders.

JNJ-64264681 is an orally active, irreversible covalent inhibitor of Bruton’s tyrosine kinase (BTK) with potent whole blood activity and exceptional kinome selectivity. It exhibits potential efficacy in treatment for B-cell malignancies and autoimmune disorders.

JNJ-64264681 is an orally active, irreversible covalent inhibitor of Bruton’s tyrosine kinase (BTK) with potent whole blood activity and exceptional kinome selectivity. It exhibits potential efficacy in treatment for B-cell malignancies and autoimmune disorders.

Ralometostat (TNG908) is a potent, selective, and brain-penetrant inhibitor of PRMT5 with an IC50 of 4 μM, acting through an MTA-cooperative mechanism. It also shows antitumor activity in a xenograft model.

Ralometostat (TNG908) is a potent, selective, and brain-penetrant inhibitor of PRMT5 with an IC50 of 4 μM, acting through an MTA-cooperative mechanism. It also shows antitumor activity in a xenograft model.

Ralometostat (TNG908) is a potent, selective, and brain-penetrant inhibitor of PRMT5 with an IC50 of 4 μM, acting through an MTA-cooperative mechanism. It also shows antitumor activity in a xenograft model.

Glesatinib(MGCD265) is an orally bioavailable potent dual inhibitor of c-MET and SMO. Glesatinib counteracts P-glycoprotein (P-gp) mediated multidrug resistance (MDR) in non-small cell lung cancer (NSCLC).